MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Kymera Therapeutics Inc

Cerrado

SectorSalud

26.35 4.48

Resumen

Variación precio

24h

Actual

Mínimo

24.28

Máximo

26.79

Métricas clave

By Trading Economics

Ingresos

-8.3M

-71M

Ventas

3.7M

7.4M

BPA

-0.89

Margen de beneficio

-956.884

Empleados

188

EBITDA

-8.3M

-69M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+114.94% upside

Dividendos

By Dow Jones

Próximas Ganancias

2 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-363M

1.9B

Apertura anterior

21.87

Cierre anterior

26.35

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

180 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Kymera Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 03:00 UTC

Principales Noticias

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9 jul 2024, 09:05 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Kymera Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

114.94% repunte

Estimación a 12 meses

Media 58.83 USD  114.94%

Máximo 97 USD

Mínimo 49 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kymera Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

12

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 30.39Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

180 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.